| Citigroup, Inc (NYSE: C) Downgrades Genzyme (NASDAQ: GENZ), Boosts Price Target - American Banking News |
|
|
American Banking NewsThe Company's product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune ...Citigroup Downgrades Genzyme (GENZ) to Hold StreetInsider.com (subscription)Hostile Bid in the Works for Genzyme Corp (NASDAQ: GENZ), Citigroup, Inc (NYSE ... read more |